Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies

Autor: Maja Ludvigsen, Ida Monrad, Marie Beck Enemark, Mette Bjerre, Julie Bondgaard Mortensen, Francesco d'Amore, Peter Kamper

Publikováno v: Mortensen, J B, Monrad, I, Enemark, M B, Ludvigsen, M, Kamper, P, Bjerre, M & d'Amore, F 2021, ' Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies ', European Journal of Haematology, vol. 107, no. 1, pp. 81-91 . https://doi.org/10.1111/ejh.13621

Background: The programmed cell death protein 1 (PD-1) and its ligand 1 and 2 (PD-L1/PD-L2) regulate the immune system, and the checkpoint pathway can be exploited by malignant cells to evade anti-tumor immune response. Soluble forms (sPD-1/sPD-L1/sP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2be4ef90bdd5a356019e5031dc973c
https://pure.au.dk/portal/da/publications/soluble-programmed-cell-death-protein-1-spd1-and-the-soluble-programmed-cell-death-ligands-1-and-2-spdl1-and-spdl2-in-lymphoid-malignancies(3ad3962f-76c5-40cf-89de-031d921bd927).html

High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Autor: Daniel Molin, Ingrid Glimelius, Rose-Marie Amini, Francesco d'Amore, Gunilla Enblad, Peter Kamper, Karin E. Smedby, Stephen Hamilton-Dutoit, Julie Bondgaard Mortensen, Maja Ludvigsen, Peter Hollander

Publikováno v: Hollander, P, Kamper, P, Smedby, K, Enblad, G, Ludvigsen, M, Mortensen, J, Amini, RM, Hamilton Dutoit, S J, d'Amore, F A, Molin, D & Glimelius, I 2017, ' High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome ', Blood Advances, vol. 1, no. 18, pp. 1427-1439 . https://doi.org/10.1182/bloodadvances.2017006346

Immune checkpoint inhibition targeting the programmed death receptor (PD)-1 pathway is a novel treatment approach in relapsed and refractory classical Hodgkin lymphoma (cHL). Identifying patients with a high risk of treatment failure could support th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b179f060abdf46d6fa388ce5a6d7620
https://doi.org/10.1182/bloodadvances.2017006346

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Autor: Thomas Relander, Elisa Jacobsen Pulczynski, Peter Kamper, Peter de Nully Brown, Michael Roost Clausen, Lars C. Gormsen, Ida Blok Sillesen, Grethe Lauritzsen, Hans Bentzen, Francesco d'Amore, Wolfgang Willenbacher, Michael Thorsgaard, Julie Bondgaard Mortensen, Jette Soenderskov Goerloev, Michael Panny, Erik Segel, Sirpa Leppä

Publikováno v: Aarhus University
University of Helsinki
Clausen, M R, Leppa, S, Brown, P D N, Goerloev, J S, Panny, M, Willenbacher, W, Sillesen, I B, Segel, E, Bentzen, H H N, Thorsgaard, M, Pulczynski, E J, Kamper, P, Gormsen, L C, Mortensen, J, Lauritzsen, G, Relander, T & d'Amore, F 2016, ' The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B-and T-Cell Phenotype-Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial) ', Blood, vol. 128, no. 22, pp. 1782-1782 .

Background: Aggressive non-Hodgkin lymphoma (aNHL) relapsing after high-dose therapy or, in not transplant-eligible patients, after 1st-line chemotherapy represents an unmet clinical need. Therefore, we aimed at evaluating a salvage combination regim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d234ac55d5dd52f061f4b1420dbfd06f
https://doi.org/10.1182/blood.v128.22.1782.1782